HAEM5:Volunteer Assignments and Opportunities: Difference between revisions
| [unchecked revision] | [checked revision] |
No edit summary |
No edit summary |
||
| (91 intermediate revisions by 9 users not shown) | |||
| Line 1: | Line 1: | ||
Welcome! | Ian Welcome! | ||
'''A new version of the Heme/Lymphoid book (5th edition) is in beta form on the WHO website with publication of a final form anticipated in 2024; we're aligning the related CCGA content to the new structure.''' | '''A new version of the Heme/Lymphoid book (5th edition) is in beta form on the WHO website with publication of a final form anticipated in 2024; we're aligning the related CCGA content to the new structure.''' | ||
| Line 10: | Line 10: | ||
*To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest. | *To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest. | ||
*Note - "NEW (No Prior)" in the 4th edition columns means either the disease is a new entity in the 5th edition or the disease was present in the 4th edition without content previously added. | *Note - "NEW (No Prior)" in the 4th edition columns means either the disease is a new entity in the 5th edition or the disease was present in the 4th edition without content previously added. | ||
__TOC__ | |||
<br /> | <br /> | ||
{| class="wikitable" style="margin:auto" | {| class="wikitable sortable" style="margin:auto" | ||
|+<big>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (5th Edition) Content</big> | |+<big>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (5th Edition) Content</big> | ||
|- | |- | ||
| Line 23: | Line 25: | ||
!Prior Notes (4th Edition) | !Prior Notes (4th Edition) | ||
|- | |- | ||
|CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS) | | | ||
====CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS)==== | |||
| | | | ||
----<br /> | ----<br /> | ||
| Line 54: | Line 57: | ||
|- | |- | ||
|[[HAEM5:Clonal haematopoiesis|Clonal haematopoiesis]]||Disease||Meenakshi Mehrotra | |[[HAEM5:Clonal haematopoiesis|Clonal haematopoiesis]]||Disease||Meenakshi Mehrotra | ||
|4/8/24 | |4/8/24, email again in 9/29/25; Meenakshi confirmed om 9/30/25. | ||
| ||Pending|| ||Fabiola Quintero-Rivera (FQR)|| || | | ||Pending|| ||Fabiola Quintero-Rivera (FQR)|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 62: | Line 65: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Clonal cytopenias of undetermined significance|Clonal cytopenias of undetermined significance]]||Disease|| || || | |[[HAEM5:Clonal cytopenias of undetermined significance|Clonal cytopenias of undetermined significance]]||Disease||Zejuan Li | ||
|10/3/2025 | |||
| ||Pending|| ||FQR|| || | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 69: | Line 74: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Chronic myeloid leukaemia|Chronic myeloid leukaemia]]||Disease|| | |[[HAEM5:Chronic myeloid leukaemia|Chronic myeloid leukaemia]]||Disease||J . Reid||9/29/25|| || || ||FQR|| || | ||
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive | |Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive | ||
|Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | |Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | ||
| Line 84: | Line 89: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Chronic eosinophilic leukaemia|Chronic eosinophilic leukaemia]]||Disease|| | |[[HAEM5:Chronic eosinophilic leukaemia|Chronic eosinophilic leukaemia]]||Disease||Daynna Wolff | ||
| || || || ||FQR|| || | |10/14/25|| || || ||FQR|| || | ||
|Chronic Eosinophilic Leukemia, Not Otherwise Specified | |Chronic Eosinophilic Leukemia, Not Otherwise Specified | ||
|Chelsea D. Kramish; Daynna J.Wolff | |Chelsea D. Kramish; Daynna J.Wolff | ||
| Line 92: | Line 97: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Polycythaemia vera|Polycythaemia vera]]||Disease|| | |[[HAEM5:Polycythaemia vera|Polycythaemia vera]]||Disease|| | ||
| || || || ||FQR|| || | | || || || ||FQR|| || | ||
|Polycythemia Vera (PV) | |Polycythemia Vera (PV) | ||
| Line 100: | Line 105: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Essential thrombocythaemia|Essential thrombocythaemia]]||Disease|| | |[[HAEM5:Essential thrombocythaemia|Essential thrombocythaemia]]||Disease||Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN | ||
| || || || ||FQR|| || | |10/1/25|| ||Pending|| ||FQR|| || | ||
|Essential Thrombocythemia (ET) | |Essential Thrombocythemia (ET) | ||
|Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN | |Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN | ||
| Line 127: | Line 132: | ||
| | | | ||
|FQR has emailed SR several times, last 4/20/22 | |FQR has emailed SR several times, last 4/20/22 | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:Myeloproliferative neoplasm, NOS|Myeloproliferative neoplasm, NOS]]||Disease||PENDING | |[[HAEM5:Myeloproliferative neoplasm, NOS|Myeloproliferative neoplasm, NOS]]||Disease||PENDING | ||
| Line 167: | Line 188: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Myelodysplastic neoplasm with low blasts and SF3B1 mutation|Myelodysplastic neoplasm with low blasts and SF3B1 mutation]]||Disease|| | |[[HAEM5:Myelodysplastic neoplasm with low blasts and SF3B1 mutation|Myelodysplastic neoplasm with low blasts and SF3B1 mutation]]||Disease|| | ||
| || || || ||FQR|| || | | || || || ||FQR|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 175: | Line 196: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Myelodysplastic neoplasm with biallelic TP53 inactivation|Myelodysplastic neoplasm with biallelic TP53 inactivation]]||Disease||Eric McGinnis (assigned to new 5th edition page - FQR is this reviewed?)|| || || || ||FQR|| || | |[[HAEM5:Myelodysplastic neoplasm with biallelic TP53 inactivation|Myelodysplastic neoplasm with biallelic TP53 inactivation]]||Disease||Eric McGinnis (assigned to new 5th edition page - FQR is this reviewed?) YES fqr 9/29/25|| || || || ||FQR|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 203: | Line 224: | ||
| | | | ||
| | | | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:Childhood myelodysplastic neoplasm with low blasts|Childhood myelodysplastic neoplasm with low blasts]]||Disease||PENDING | |[[HAEM5:Childhood myelodysplastic neoplasm with low blasts|Childhood myelodysplastic neoplasm with low blasts]]||Disease||PENDING | ||
| Line 244: | Line 281: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm, NOS|Myelodysplastic/myeloproliferative neoplasm, NOS]]||Disease|| | |[[HAEM5:Myelodysplastic/myeloproliferative neoplasm, NOS|Myelodysplastic/myeloproliferative neoplasm, NOS]]||Disease|| | ||
| || || || ||FQR|| || | | || || || ||FQR|| || | ||
|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable | |Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable | ||
| Line 254: | Line 291: | ||
|[[HAEM5:Acute promyelocytic leukaemia with PML::RARA fusion|Acute promyelocytic leukaemia with PML::RARA fusion]] | |[[HAEM5:Acute promyelocytic leukaemia with PML::RARA fusion|Acute promyelocytic leukaemia with PML::RARA fusion]] | ||
|Disease | |Disease | ||
| | |Rabail Aslam, MD (trainee); | ||
Shashi Shetty, Ph.D. | |||
| | |7/1/24 | ||
| | | | ||
|Pending | |||
| | | | ||
|Jennelle Hodge (JH)/ Malini Sathanoori (MS) | |Jennelle Hodge (JH)/ Malini Sathanoori (MS) | ||
| Line 270: | Line 308: | ||
|[[HAEM5:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion]] | |[[HAEM5:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion]] | ||
|Disease | |Disease | ||
| | |Mayuri Shende (trainee); | ||
Scott Turner (mentor)<br /> | |||
| | |9/22/24 | ||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 286: | Line 325: | ||
|[[HAEM5:Acute myeloid leukaemia with CBFB::MYH11 fusion|Acute myeloid leukaemia with CBFB::MYH11 fusion]] | |[[HAEM5:Acute myeloid leukaemia with CBFB::MYH11 fusion|Acute myeloid leukaemia with CBFB::MYH11 fusion]] | ||
|Disease | |Disease | ||
| | |Mayuri Shende (trainee); | ||
Scott Turner (mentor)<br /> | |||
| | |9/22/24 | ||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 302: | Line 342: | ||
|[[HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion|Acute myeloid leukaemia with DEK::NUP214 fusion]] | |[[HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion|Acute myeloid leukaemia with DEK::NUP214 fusion]] | ||
|Disease | |Disease | ||
| | |Jennelle C. Hodge, PhD | ||
| | | | ||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 316: | Line 356: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion|Acute myeloid leukaemia with RBM15::MRTFA fusion]] | !Disease (5th Edition) | ||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
|[[HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion|Acute myeloid leukaemia with RBM15::MRTFA fusion]] | |||
|Disease | |Disease | ||
| | |Jennelle C. Hodge, PhD | ||
| | | | ||
| | | | ||
|Complete | |||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 334: | Line 390: | ||
|[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]] | |[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]] | ||
|Disease | |Disease | ||
| | |Xinxiu Xu (trainee); | ||
| | Malini Sathanoori, Ph.D. | ||
|4/15/25 | |||
| | | | ||
| | | | ||
| Line 350: | Line 407: | ||
|[[HAEM5:Acute myeloid leukaemia with KMT2A rearrangement|Acute myeloid leukaemia with KMT2A rearrangement]] | |[[HAEM5:Acute myeloid leukaemia with KMT2A rearrangement|Acute myeloid leukaemia with KMT2A rearrangement]] | ||
|Disease | |Disease | ||
| | |Rabail Aslam, MD (trainee); | ||
Shashi Shetty, Ph.D. | |||
| | |7/1/24 | ||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 366: | Line 424: | ||
|[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]] | |[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]] | ||
|Disease | |Disease | ||
| | |Gordana Raca MD PhD, | ||
|9/8/25 | |||
| | |||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 382: | Line 440: | ||
|[[HAEM5:Acute myeloid leukaemia with NUP98 rearrangement|Acute myeloid leukaemia with NUP98 rearrangement]] | |[[HAEM5:Acute myeloid leukaemia with NUP98 rearrangement|Acute myeloid leukaemia with NUP98 rearrangement]] | ||
|Disease | |Disease | ||
|Eric McGinnis, MD | |Eric McGinnis, MD; | ||
Fatma Al-Bulushi (trannee) | |||
|12/20/23 | |12/20/23 | ||
| | | | ||
| | |Pending | ||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 398: | Line 457: | ||
|[[HAEM5:Acute myeloid leukaemia with NPM1 mutation|Acute myeloid leukaemia with NPM1 mutation]] | |[[HAEM5:Acute myeloid leukaemia with NPM1 mutation|Acute myeloid leukaemia with NPM1 mutation]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 405: | Line 464: | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | |emailed request on 7/16/24. No response as of 9/7/25. | ||
Prior author: Xinjie Xu, PhD, FACMG | |||
Open to new author | |||
|Acute Myeloid Leukemia (AML) with Mutated NPM1 | |Acute Myeloid Leukemia (AML) with Mutated NPM1 | ||
|Xinjie Xu, PhD, FACMG | |Xinjie Xu, PhD, FACMG | ||
|Complete | |Complete | ||
| | | | ||
|Add WHO reference | |Add WHO reference<br /> | ||
|- | |- | ||
|[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]] | |[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]] | ||
|Disease | |Disease | ||
| | |Xinxiu Xu (trainee); | ||
| | Malini Sathanoori, Ph.D. | ||
|4/15/25 | |||
| | | | ||
| | | | ||
| Line 430: | Line 493: | ||
|[[HAEM5:Acute myeloid leukaemia, myelodysplasia-related|Acute myeloid leukaemia, myelodysplasia-related]] | |[[HAEM5:Acute myeloid leukaemia, myelodysplasia-related|Acute myeloid leukaemia, myelodysplasia-related]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 437: | Line 500: | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | |emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25 | ||
|Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes | |Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes | ||
|Fei Yang, MD, FACMG <br> Oregon Health & Science University | |Fei Yang, MD, FACMG <br> Oregon Health & Science University | ||
| Line 462: | Line 525: | ||
|[[HAEM5:Acute myeloid leukaemia with minimal differentiation|Acute myeloid leukaemia with minimal differentiation]] | |[[HAEM5:Acute myeloid leukaemia with minimal differentiation|Acute myeloid leukaemia with minimal differentiation]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 469: | Line 532: | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | |Prior author: Celeste Eno, PhD | ||
Open to new author | |||
|Acute Myeloid Leukemia (AML) with Minimal Differentiation | |Acute Myeloid Leukemia (AML) with Minimal Differentiation | ||
|Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles, Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine | |Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles, Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine | ||
| Line 475: | Line 540: | ||
| | | | ||
| | | | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]] | |[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]] | ||
|Disease | |Disease | ||
| | |Jennelle C. Hodge, PhD | ||
| | | | ||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 494: | Line 575: | ||
|[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]] | |[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]] | ||
|Disease | |Disease | ||
| | |Jennelle C. Hodge, PhD | ||
| | | | ||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 510: | Line 591: | ||
|[[HAEM5:Acute basophilic leukaemia|Acute basophilic leukaemia]] | |[[HAEM5:Acute basophilic leukaemia|Acute basophilic leukaemia]] | ||
|Disease | |Disease | ||
| | |Ashwini Yenamandra PhD FACMG | ||
|5/1/24 | |||
| | |||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 526: | Line 607: | ||
|[[HAEM5:Acute myelomonocytic leukaemia|Acute myelomonocytic leukaemia]] | |[[HAEM5:Acute myelomonocytic leukaemia|Acute myelomonocytic leukaemia]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 533: | Line 614: | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | |emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25 | ||
|Acute Myelomonocytic Leukemia | |Acute Myelomonocytic Leukemia | ||
|Fei Yang, MD, FACMG <br> Oregon Health & Science University | |Fei Yang, MD, FACMG <br> Oregon Health & Science University | ||
| Line 542: | Line 623: | ||
|[[HAEM5:Acute monocytic leukaemia|Acute monocytic leukaemia]] | |[[HAEM5:Acute monocytic leukaemia|Acute monocytic leukaemia]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 549: | Line 630: | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | |emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25 | ||
|Acute Monoblastic and Monocytic Leukemia | |Acute Monoblastic and Monocytic Leukemia | ||
|Fei Yang, MD, FACMG <br> Oregon Health & Science University | |Fei Yang, MD, FACMG <br> Oregon Health & Science University | ||
| Line 558: | Line 639: | ||
|[[HAEM5:Acute erythroid leukaemia|Acute erythroid leukaemia]] | |[[HAEM5:Acute erythroid leukaemia|Acute erythroid leukaemia]] | ||
|Disease | |Disease | ||
| | |Ashwini Yenamandra PhD FACMG | ||
|5/1/24 | |||
| | |||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 574: | Line 655: | ||
|[[HAEM5:Acute megakaryoblastic leukaemia|Acute megakaryoblastic leukaemia]] | |[[HAEM5:Acute megakaryoblastic leukaemia|Acute megakaryoblastic leukaemia]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 581: | Line 662: | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | |emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25 | ||
|Acute Megakaryoblastic Leukemia (AMKL) | |Acute Megakaryoblastic Leukemia (AMKL) | ||
|Fei Yang, MD, FACMG <br> Oregon Health & Science University | |Fei Yang, MD, FACMG <br> Oregon Health & Science University | ||
| Line 590: | Line 671: | ||
|[[HAEM5:Myeloid sarcoma|Myeloid sarcoma]] | |[[HAEM5:Myeloid sarcoma|Myeloid sarcoma]] | ||
|Disease | |Disease | ||
| | |Yalda Naeini | ||
|6/11/24 | |||
| | |||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 625: | Line 706: | ||
|[[HAEM5:Myeloid neoplasm post cytotoxic therapy|Myeloid neoplasm post cytotoxic therapy]] | |[[HAEM5:Myeloid neoplasm post cytotoxic therapy|Myeloid neoplasm post cytotoxic therapy]] | ||
|Disease | |Disease | ||
| | |Rabail Aslam, MD (trainee); | ||
Shashi Shetty, Ph.D. | |||
| | |7/1/24 | ||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 638: | Line 720: | ||
| | | | ||
|Check reference format | |Check reference format | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:Myeloid neoplasms associated with germline predisposition|Myeloid neoplasms associated with germline predisposition]] | |[[HAEM5:Myeloid neoplasms associated with germline predisposition|Myeloid neoplasms associated with germline predisposition]] | ||
|Disease | |Disease | ||
| | |Malini Sathanoori, Ph.D. | ||
|12/6/24 | |||
| | |||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 657: | Line 755: | ||
|[[HAEM5:Myeloid proliferations associated with Down syndrome|Myeloid proliferations associated with Down syndrome]] | |[[HAEM5:Myeloid proliferations associated with Down syndrome|Myeloid proliferations associated with Down syndrome]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 664: | Line 762: | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | |Prior author: | ||
Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO | |||
|MERGE 3 PAGES --> Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Myeloid Leukemia Associated with Down Syndrome | |MERGE 3 PAGES --> Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Myeloid Leukemia Associated with Down Syndrome | ||
|Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO | |Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO | ||
| Line 756: | Line 855: | ||
|[[HAEM5:Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion]] | |[[HAEM5:Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion]] | ||
|Disease | |Disease | ||
|Mayuri Shende (trainee); | |||
Scott Turner (mentor)<br /> | |||
|9/22/24 | |||
| | | | ||
| | |Pending | ||
| | | | ||
|FQR | |FQR | ||
| Line 772: | Line 872: | ||
|[[HAEM5:Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes]] | |[[HAEM5:Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes]] | ||
|Disease | |Disease | ||
|Rolando Garcia | |||
|2/7/2025 | |||
| | | | ||
| | |Pending | ||
| | | | ||
|FQR | |FQR | ||
| Line 801: | Line 901: | ||
| | | | ||
| | | | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]] | |[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]] | ||
| Line 836: | Line 952: | ||
|[[HAEM5:Mixed-phenotype acute leukaemia, B/myeloid|Mixed-phenotype acute leukaemia, B/myeloid]] | |[[HAEM5:Mixed-phenotype acute leukaemia, B/myeloid|Mixed-phenotype acute leukaemia, B/myeloid]] | ||
|Disease | |Disease | ||
| | |Rabail Aslam, MD (trainee); | ||
Shashi Shetty, Ph.D. | |||
|7/1/24 | |||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |||
|JH_MS | |||
| | | | ||
| | | | ||
| Line 859: | Line 976: | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | |emailed 5/1/24 | ||
|Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified | |Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified | ||
|Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine | |Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine | ||
| Line 868: | Line 985: | ||
|[[HAEM5:Mixed-phenotype acute leukaemia, rare types|Mixed-phenotype acute leukaemia, rare types]] | |[[HAEM5:Mixed-phenotype acute leukaemia, rare types|Mixed-phenotype acute leukaemia, rare types]] | ||
|Disease | |Disease | ||
| | |Daynna Wolff, PhD | ||
|5/9/24 | |||
| | |||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 900: | Line 1,017: | ||
|[[HAEM5:Acute undifferentiated leukaemia|Acute undifferentiated leukaemia]] | |[[HAEM5:Acute undifferentiated leukaemia|Acute undifferentiated leukaemia]] | ||
|Disease | |Disease | ||
| | |Rabail Aslam, MD (trainee); | ||
Shashi Shetty, Ph.D. | |||
| | |7/1/24 | ||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 914: | Line 1,032: | ||
|Check reference format | |Check reference format | ||
|- | |- | ||
|CHAPTER 3 (HISTIOCYTIC/DENRITIC CELL NEOPLASMS) | !Disease (5th Edition) | ||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
| | |||
====CHAPTER 3 (HISTIOCYTIC/DENRITIC CELL NEOPLASMS)==== | |||
| | | | ||
----<br /> | ----<br /> | ||
| Line 962: | Line 1,097: | ||
|[[HAEM5:Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm]] | |[[HAEM5:Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm]] | ||
|Disease | |Disease | ||
| | |Daynna Wolff | ||
| | |5/3/2025 | ||
| | |8/3/2025 | ||
| | |Pending | ||
| | | | ||
|GC | |GC | ||
| Line 978: | Line 1,113: | ||
|[[HAEM5:Langerhans cell histiocytosis|Langerhans cell histiocytosis]] | |[[HAEM5:Langerhans cell histiocytosis|Langerhans cell histiocytosis]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 989: | Line 1,124: | ||
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland | |Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland | ||
|Complete | |Complete | ||
|5/19/2022<br /> | |5/19/2022 Emailed 5/6/2025, no reply<br /> | ||
|Date completed by author: 04/28/2022 | |Date completed by author: 04/28/2022 | ||
|- | |- | ||
|[[HAEM5:Langerhans cell sarcoma|Langerhans cell sarcoma]] | |[[HAEM5:Langerhans cell sarcoma|Langerhans cell sarcoma]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 1,005: | Line 1,140: | ||
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland | |Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland | ||
|Complete | |Complete | ||
|5/19/2022<br /> | |5/19/2022 Emailed 5/6/2025, no reply<br /> | ||
|Date completed by author: 04/28/2022 | |Date completed by author: 04/28/2022 | ||
|- | |- | ||
| Line 1,026: | Line 1,161: | ||
|[[HAEM5:Interdigitating dendritic cell sarcoma|Interdigitating dendritic cell sarcoma]] | |[[HAEM5:Interdigitating dendritic cell sarcoma|Interdigitating dendritic cell sarcoma]] | ||
|Disease | |Disease | ||
| | |Muhammad Zulfiqar, MD | ||
| | |7/4/2025 | ||
| | |10/4/2025 | ||
| | |Pending | ||
| | | | ||
|GC | |GC | ||
| Line 1,042: | Line 1,177: | ||
|[[HAEM5:Juvenile xanthogranuloma|Juvenile xanthogranuloma]] | |[[HAEM5:Juvenile xanthogranuloma|Juvenile xanthogranuloma]] | ||
|Disease | |Disease | ||
| | |Mayuri Shende (trainee); | ||
| | Scott Turner (mentor)<br /> | ||
| | |9/22/24 | ||
| | |12/22/24 Emailed 9/4/2025 to remind | ||
|Pending | |||
| | | | ||
|GC | |GC | ||
| Line 1,058: | Line 1,194: | ||
|[[HAEM5:Erdheim-Chester disease|Erdheim-Chester disease]] | |[[HAEM5:Erdheim-Chester disease|Erdheim-Chester disease]] | ||
|Disease | |Disease | ||
| | |Mayuri Shende (trainee); | ||
| | Scott Turner (mentor)<br /> | ||
| | |9/22/24 | ||
| | |12/22/24 Emailed 9/4/2025 to remind | ||
|Pending | |||
| | | | ||
|GC | |GC | ||
| Line 1,074: | Line 1,211: | ||
|[[HAEM5:Rosai-Dorfman Disease|Rosai-Dorfman Disease]] | |[[HAEM5:Rosai-Dorfman Disease|Rosai-Dorfman Disease]] | ||
|Disease | |Disease | ||
| | |Mayuri Shende (trainee); | ||
| | Scott Turner (mentor)<br /> | ||
| | |9/22/24 | ||
| | |12/22/24 Emailed 9/4/2025 to remind | ||
|Pending | |||
| | | | ||
|GC | |GC | ||
| Line 1,106: | Line 1,244: | ||
|[[HAEM5:Histiocytic sarcoma|Histiocytic sarcoma]] | |[[HAEM5:Histiocytic sarcoma|Histiocytic sarcoma]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 1,118: | Line 1,256: | ||
|Complete | |Complete | ||
|10/01/2021 | |10/01/2021 | ||
|Date completed by author: 10/01/2021 | |Date completed by author: 10/01/2021. Emailed both authors 5/1/2025, no reply. | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|CHAPTER 4 (B-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS) | | | ||
====CHAPTER 4 (B-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)==== | |||
| | | | ||
----<br /> | ----<br /> | ||
| Line 1,152: | Line 1,307: | ||
|[[HAEM5:Reactive B-cell rich lymphoid proliferations that can mimic lymphoma|Reactive B-cell rich lymphoid proliferations that can mimic lymphoma]] | |[[HAEM5:Reactive B-cell rich lymphoid proliferations that can mimic lymphoma|Reactive B-cell rich lymphoid proliferations that can mimic lymphoma]] | ||
|Disease | |Disease | ||
| | |Muhammad Zulfiqar, MD | ||
| | |7/4/2025 | ||
| | |10/4/2025 Emailed 9/4/2025 to remind | ||
| | |Pending | ||
| | | | ||
|GC | |GC | ||
| Line 1,168: | Line 1,323: | ||
|[[HAEM5:IgG4-related disease|IgG4-related disease]] | |[[HAEM5:IgG4-related disease|IgG4-related disease]] | ||
|Disease | |Disease | ||
| | |Muhammad Zulfiqar, MD | ||
| | |7/4/2025 | ||
| | |10/4/2025 Emailed 9/4/2025 to remind | ||
| | |Pending | ||
| | | | ||
|GC | |GC | ||
| Line 1,216: | Line 1,371: | ||
|[[HAEM5:KSHV/HHV8-associated multicentric Castleman disease|KSHV/HHV8-associated multicentric Castleman disease]] | |[[HAEM5:KSHV/HHV8-associated multicentric Castleman disease|KSHV/HHV8-associated multicentric Castleman disease]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 1,227: | Line 1,382: | ||
|Sudha Arumugam, MD | |Sudha Arumugam, MD | ||
|Complete | |Complete | ||
|01/24/2022 | |01/24/2022. Emailed 5/1/2025, no response | ||
|Date completed by author: 01/24/2022 | |Date completed by author: 01/24/2022 | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]] | ||
|Disease | |Disease | ||
| | |To be covered in B-ALL, NOS | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | |Sumi Kitahara (SK) | ||
| | | | ||
| | | | ||
| Line 1,248: | Line 1,419: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy]] | ||
|Disease | |Disease | ||
| | |Miguel Gonzalez Mancera, MD | ||
| | | | ||
| | | | ||
|Complete (pending review by SK) | |||
| | | | ||
| | |SK | ||
| | | | ||
| | | | ||
| Line 1,264: | Line 1,435: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with hypodiploidy|B-lymphoblastic leukaemia/lymphoma with hypodiploidy]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with hypodiploidy|B-lymphoblastic leukaemia/lymphoma with hypodiploidy]] | ||
|Disease | |Disease | ||
| | |Miguel Gonzalez Mancera, MD | ||
| | | | ||
| | | | ||
|Complete (pending review by SK) | |||
| | | | ||
| | |SK | ||
| | | | ||
| | | | ||
| Line 1,280: | Line 1,451: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with iAMP21|B-lymphoblastic leukaemia/lymphoma with iAMP21]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with iAMP21|B-lymphoblastic leukaemia/lymphoma with iAMP21]] | ||
|Disease | |Disease | ||
|Holli Drendel | |Holli Drendel, PhD | ||
|Nov 11/2025 | |||
| | | | ||
|Pending | |||
| | | | ||
| | |SK | ||
| | | | ||
| | | | ||
| Line 1,296: | Line 1,467: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]] | ||
|Disease | |Disease | ||
| | |Karin Miller, MD | ||
|10/9/2025 | |||
|12/5/2025 | |||
| | | | ||
| | | | ||
| | |SK | ||
| | | | ||
| | | | ||
| Line 1,312: | Line 1,483: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]] | ||
|Disease | |Disease | ||
| | |Mark G. Evans, MD | ||
| | |10/1/2025 | ||
| | |11/17/2025 | ||
| | |Complete (pending review by SK) | ||
| | |11/8/2025 | ||
| | |SK | ||
| | |Pending | ||
| | | | ||
|B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | |B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | ||
| Line 1,328: | Line 1,499: | ||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement]] | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement]] | ||
|Disease | |Disease | ||
| | |Gokce A. Toruner, MD, PhD | ||
|10/9/2025 | |||
|11/5/2025 | |||
|Pending | |||
| | | | ||
| | |SK | ||
| | | | ||
| | | | ||
| Line 1,344: | Line 1,515: | ||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion]] | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion]] | ||
|Disease | |Disease | ||
| | |Gokce A. Toruner, MD, PhD | ||
| | |10/8/2025 | ||
|12/1/2025 | |||
|Pending | |||
| | | | ||
| | |SK | ||
| | | | ||
| | | | ||
| Line 1,360: | Line 1,531: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features]] | ||
|Disease | |Disease | ||
|Lei Zhang, PhD | |||
Michelle Fan (trainee) | |||
|10/10/2025 | |||
|12/22/2025 | |||
|Pending | |||
| | | | ||
| | |SK | ||
| | | | ||
| | | | ||
| Line 1,376: | Line 1,548: | ||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion]] | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion]] | ||
|Disease | |Disease | ||
| | |Miguel Gonzalez Mancera, MD | ||
|10/1/2025 | |||
| | | | ||
|Pending | |||
| | | | ||
| | |SK | ||
| | | | ||
| | | | ||
| Line 1,392: | Line 1,564: | ||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion]] | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion]] | ||
|Disease | |Disease | ||
| | |Miguel Gonzalez Mancera, MD | ||
|10/1/2025 | |||
| | | | ||
|Pending | |||
| | | | ||
| | |SK | ||
| | | | ||
| | | | ||
| Line 1,408: | Line 1,580: | ||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion|B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion]] | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion|B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion]] | ||
|Disease | |Disease | ||
|Aiko Otsubo | |Aiko Otsubo, PhD | ||
| | |10/10/2025 | ||
| | |11/24/2025 | ||
|Complete (pending SK review) | |||
|11/11/2025 | |||
|SK | |||
|Pending | |Pending | ||
| | | | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 1,424: | Line 1,596: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations]] | ||
|Disease | |Disease | ||
|Lei Zhang, PhD | |||
|10/10/2025 | |||
|12/22/2025 | |||
|Pending | |||
| | | | ||
| | |SK | ||
| | | | ||
| | | | ||
| Line 1,439: | Line 1,611: | ||
|- | |- | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma, NOS|B-lymphoblastic leukaemia/lymphoma, NOS]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma, NOS|B-lymphoblastic leukaemia/lymphoma, NOS]] | ||
|Disease | |Disease | ||
|Karin Miller, MD | |||
|10/9/2025 | |||
|11/24/2025 | |||
|Pending | |||
| | |||
|SK | |||
| | | | ||
| | | | ||
| Line 1,445: | Line 1,623: | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | |- | ||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|RESOLVE 4th edition ALL-Related NON-WHO entities content | |RESOLVE 4th edition ALL-Related NON-WHO entities content | ||
|B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4 | |B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4 | ||
B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6 | |||
B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements | |||
B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions | |||
B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19) | |||
B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11) | |||
|ISSUE- FIX | |ISSUE- FIX | ||
| Line 1,473: | Line 1,676: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING; Shashirekha Shetty | !Disease (5th Edition) | ||
| || || || ||Shivani Golem (SG) | !Page Type | ||
| || | !<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | ||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING; Shashirekha Shetty | |||
| ||9/4/2025 sent E-mail reminder|| || ||Shivani Golem (SG) | |||
| || | |||
|Monoclonal B-cell Lymphocytosis | |Monoclonal B-cell Lymphocytosis | ||
|Tsigab Bahta Hagos (trainee) / Shashirekha Shetty | |Tsigab Bahta Hagos (trainee) / Shashirekha Shetty | ||
| Line 1,482: | Line 1,701: | ||
|Assigned 12/19/2022 with completion date of 1/19/2023 | |Assigned 12/19/2022 with completion date of 1/19/2023 | ||
|- | |- | ||
|[[HAEM5:Chronic lymphocytic leukaemia/small lymphocytic lymphoma|Chronic lymphocytic leukaemia/small lymphocytic lymphoma]]||Disease||Jaime Nagy, PhD, University of Iowa | |[[HAEM5:Chronic lymphocytic leukaemia/small lymphocytic lymphoma|Chronic lymphocytic leukaemia/small lymphocytic lymphoma]]||Disease||Jaime Nagy, PhD, University of Iowa, | ||
Renee Eigsti, MD, Pathology Services of Kalamazoo | Renee Eigsti, MD, Pathology Services of Kalamazoo, | ||
Honey Reddi, PhD, Belay Diagnostics | Honey Reddi, PhD, Belay Diagnostics | ||
| Line 1,494: | Line 1,713: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease|| | |[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease||Michael Lack, MD, KUMC (trainee); | ||
| || || || ||SG|| || | Shivani Golem | ||
|7/16/24||9/4/2025 sent E-mail reminder||PENDING|| ||SG|| ||Need new author to update latest content. Prior author cannot update the page. | |||
|Hairy Cell Leukemia | |Hairy Cell Leukemia | ||
|Snehal Patel, MD, PhD | |Snehal Patel, MD, PhD | ||
| | |Pending WHO 5th e. July 2024 | ||
| | | | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease|| | |[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease||Madhu Pantrangi | ||
| || || || ||SG|| || | |4/15/25|| ||9/4/2025 sent E-mail reminder|| ||SG|| ||Need new author to update latest content. Prior author cannot update the page. | ||
|Splenic Marginal Zone Lymphoma | |Splenic Marginal Zone Lymphoma | ||
|Snehal Patel, MD, PhD | |Snehal Patel, MD, PhD | ||
| Line 1,511: | Line 1,731: | ||
|- | |- | ||
|[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease|| | |[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease|| | ||
| || || || ||SG|| || | | || || || ||SG|| ||Need new author to update latest content. Prior author cannot update the page. | ||
|Splenic Diffuse Red Pulp Small B-cell Lymphoma | |Splenic Diffuse Red Pulp Small B-cell Lymphoma | ||
|Snehal Patel, MD, PhD | |Snehal Patel, MD, PhD | ||
| Line 1,527: | Line 1,747: | ||
|SG | |SG | ||
| | | | ||
| | |Need new author to update latest content. Prior author cannot update the page. | ||
|Hairy Cell Leukemia Variant | |Hairy Cell Leukemia Variant | ||
|Snehal Patel, MD, PhD | |Snehal Patel, MD, PhD | ||
| Line 1,536: | Line 1,756: | ||
|[[HAEM5:Lymphoplasmacytic lymphoma|Lymphoplasmacytic lymphoma]] | |[[HAEM5:Lymphoplasmacytic lymphoma|Lymphoplasmacytic lymphoma]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
|Sent e-mail to prev authors no reply | |||
| | | | ||
| | | | ||
|SG | |SG | ||
| | | | ||
| | |Email sent to request to update 2024 | ||
|(1) Lymphoplasmacytic Lymphoma + (2) Waldenstrom Macroglobulinemia | |(1) Lymphoplasmacytic Lymphoma + (2) Waldenstrom Macroglobulinemia | ||
|(1 and 2) Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD Departments of Pathology, Laboratory Medicine, and Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI) | |(1 and 2) Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD Departments of Pathology, Laboratory Medicine, and Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI) | ||
| Line 1,552: | Line 1,772: | ||
|[[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue]] | |[[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
|Sent e-mail to prev authors no reply | |||
| | | | ||
| | | | ||
|SG | |SG | ||
| | | | ||
| | |Email sent to request to update 2024 | ||
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma) | |Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma) | ||
|Whayoung Lee, MD (trainee), Fabiola Quintero-Rivera, MD, FACMG* | |Whayoung Lee, MD (trainee), Fabiola Quintero-Rivera, MD, FACMG* | ||
| Line 1,570: | Line 1,790: | ||
|[[HAEM5:Primary cutaneous marginal zone lymphoma|Primary cutaneous marginal zone lymphoma]] | |[[HAEM5:Primary cutaneous marginal zone lymphoma|Primary cutaneous marginal zone lymphoma]] | ||
|Disease | |Disease | ||
|Molly Walkenhorst | |||
| | | | ||
| | |9/4/2025 sent E-mail reminder | ||
| | | | ||
| | | | ||
| Line 1,579: | Line 1,799: | ||
| | | | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|Molly Walkenhorst, DO and Shivani Golem, PhD, FACMG | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| | |- | ||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:Nodal marginal zone lymphoma|Nodal marginal zone lymphoma]] | |[[HAEM5:Nodal marginal zone lymphoma|Nodal marginal zone lymphoma]] | ||
|Disease | |Disease | ||
| | |Andrew Ly | ||
| | | | ||
|9/4/2025 sent E-mail reminder | |||
| | | | ||
| | | | ||
| Line 1,602: | Line 1,838: | ||
|[[HAEM5:Paediatric nodal marginal zone lymphoma|Paediatric nodal marginal zone lymphoma]] | |[[HAEM5:Paediatric nodal marginal zone lymphoma|Paediatric nodal marginal zone lymphoma]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 1,609: | Line 1,845: | ||
|SG | |SG | ||
| | | | ||
| | |Need new author to update latest content. Prior authors cannot update the page. | ||
|Paediatric Nodal Marginal Zone Lymphoma | |Paediatric Nodal Marginal Zone Lymphoma | ||
|* Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD | |* Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD | ||
|Complete | |Complete; Need new author to update latest content. Primary author cannot update the page. | ||
|11/11/2020 | |11/11/2020 | ||
| | | | ||
| Line 1,620: | Line 1,856: | ||
|Rachel D. Burnside, PhD, MBA, FACMGG | |Rachel D. Burnside, PhD, MBA, FACMGG | ||
|7/28/2023 | |7/28/2023 | ||
| | |9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024 | ||
|Pending | |Pending | ||
| | | | ||
| Line 1,636: | Line 1,872: | ||
|Rachel D. Burnside, PhD, MBA, FACMGG | |Rachel D. Burnside, PhD, MBA, FACMGG | ||
|7/28/2023 | |7/28/2023 | ||
| | |9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024 | ||
|Pending | |Pending | ||
| | | | ||
| Line 1,650: | Line 1,886: | ||
|[[HAEM5:Paediatric-type follicular lymphoma|Paediatric-type follicular lymphoma]] | |[[HAEM5:Paediatric-type follicular lymphoma|Paediatric-type follicular lymphoma]] | ||
|Disease | |Disease | ||
| | |Rachel D. Burnside, PhD, MBA, FACMGG | ||
| | | | ||
|9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024 | |||
| | | | ||
| | | | ||
|SG | |SG | ||
| | | | ||
| | |Need new author to update latest content. Prior authors cannot update the page. | ||
|Paediatric-Type Follicular Lymphoma | |Paediatric-Type Follicular Lymphoma | ||
|*Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG | |*Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG | ||
|Complete | |Complete; Need new author to update latest content. Primary author cannot update the page. | ||
|8/16/2020 | |8/16/2020 | ||
| | | | ||
| Line 1,668: | Line 1,904: | ||
|Rachel D. Burnside, PhD, MBA, FACMGG | |Rachel D. Burnside, PhD, MBA, FACMGG | ||
|7/28/2023 | |7/28/2023 | ||
| | |9/4/2025 sent email reminder; Last E-mail to Dr. Burnside no reply 7/17/ | ||
|Pending | |Pending | ||
| | | | ||
| Line 1,682: | Line 1,918: | ||
|[[HAEM5:Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle centre lymphoma]] | |[[HAEM5:Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle centre lymphoma]] | ||
|Disease | |Disease | ||
| | |Linlin Gao | ||
| | | | ||
|9/4/2025 Sent E-mail to remind | |||
| | | | ||
| | | | ||
| Line 1,698: | Line 1,934: | ||
|[[HAEM5:In situ mantle cell neoplasm|In situ mantle cell neoplasm]] | |[[HAEM5:In situ mantle cell neoplasm|In situ mantle cell neoplasm]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 1,716: | Line 1,952: | ||
|PENDING | |PENDING | ||
| | | | ||
| | |9/4/2025 set E-mail reminder | ||
| | | | ||
| | | | ||
| Line 1,730: | Line 1,966: | ||
|[[HAEM5:Leukaemic non-nodal mantle cell lymphoma|Leukaemic non-nodal mantle cell lymphoma]] | |[[HAEM5:Leukaemic non-nodal mantle cell lymphoma|Leukaemic non-nodal mantle cell lymphoma]] | ||
|Disease | |Disease | ||
|Farhan Sami | |||
| | | | ||
| | |9/4/2025 sent E-mail reminder | ||
| | | | ||
| | | | ||
| Line 1,739: | Line 1,975: | ||
| | | | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|Farhan Sami, MD and Shivani Golem, PhD, FACMG | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| | |- | ||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:Transformations of indolent B-cell lymphomas|Transformations of indolent B-cell lymphomas]] | |[[HAEM5:Transformations of indolent B-cell lymphomas|Transformations of indolent B-cell lymphomas]] | ||
|Disease | |Disease | ||
|Farhan Sami | |||
| | | | ||
| | |9/4/2025 sent E-mail reminder | ||
| | | | ||
| | | | ||
| Line 1,755: | Line 2,007: | ||
|Include content on chronic myelomonocytic leukemia in transformation and refractory anaemia with excess blasts in transformation | |Include content on chronic myelomonocytic leukemia in transformation and refractory anaemia with excess blasts in transformation | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| | |Farhan Sami, MD and Shivani Golem, PhD, FACMG | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Diffuse large B-cell lymphoma, NOS|Diffuse large B-cell lymphoma, NOS]]||Disease|| | |[[HAEM5:Diffuse large B-cell lymphoma, NOS|Diffuse large B-cell lymphoma, NOS]]||Disease|| | ||
| || || || ||GC|| || | | || || || ||GC|| || | ||
|Diffuse Large B-cell Lymphoma, Not Otherwise Specified | |Diffuse Large B-cell Lymphoma, Not Otherwise Specified | ||
| Line 1,775: | Line 2,027: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease|| | |[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland | ||
| || || || ||GC|| || | |5/6/2025||8/6/2025 Emailed 9/4/2025 to remind|| || ||GC|| || | ||
|High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements | |High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements | ||
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland | |Kate Berry, MBBS, BBus (Hons), Pathology Queensland | ||
| Line 1,783: | Line 2,035: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease|| | |[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease|| | ||
| || || || ||GC|| || | | || || || ||GC|| || | ||
|ALK-Positive Large B-cell Lymphoma | |ALK-Positive Large B-cell Lymphoma | ||
|Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine) | |Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine) | ||
| | | | ||
| | | | ||
|Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23 | |Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23 | ||
|- | |- | ||
|[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease|| | |[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease|| | ||
| || || || ||GC|| || | | || || || ||GC|| || | ||
|Large B-cell Lymphoma with IRF4 Rearrangement | |Large B-cell Lymphoma with IRF4 Rearrangement | ||
|Afia Hasnain, MBBS, PhD | |Afia Hasnain, MBBS, PhD | ||
|Complete | |Complete | ||
|5/26/2021 | |5/26/2021. Emailed 5/7//2025, no reply | ||
| | | | ||
|- | |- | ||
|[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease|| | |[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease|| | ||
| || || || ||GC|| || | | || || || ||GC|| || | ||
|Burkitt-Like Lymphoma with 11q Aberration | |Burkitt-Like Lymphoma with 11q Aberration | ||
|Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina | |Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina | ||
| | |Complete | ||
|27/01/2022 | |27/01/2022 Emailed 5/7//2025, no reply | ||
| | | | ||
|- | |- | ||
| Line 1,814: | Line 2,066: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:EBV-positive diffuse large B-cell lymphoma|EBV-positive diffuse large B-cell lymphoma]]||Disease||Fnu Monika (trainee) | |[[HAEM5:EBV-positive diffuse large B-cell lymphoma|EBV-positive diffuse large B-cell lymphoma]]||Disease||Fnu Monika (trainee); | ||
Andrew Siref as mentor | |||
|3/22/24|| ||Pending|| ||GC|| || | |3/22/24|| ||Pending|| ||GC|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 1,829: | Line 2,082: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease|| | !Disease (5th Edition) | ||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
|[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease|| | |||
| || || || ||GC|| ||Note: previously a subset DLBCL assoc with chronic inflam | | || || || ||GC|| ||Note: previously a subset DLBCL assoc with chronic inflam | ||
|Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior) | |Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior) | ||
| Line 1,844: | Line 2,113: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease|| | |[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease|| | ||
| || || || ||GC|| || | | || || || ||GC|| || | ||
|Plasmablastic Lymphoma | |Plasmablastic Lymphoma | ||
| Line 1,852: | Line 2,121: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease|| | |[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease||Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital | ||
| | | |6/28/2025 | ||
|9/28/2025 Emailed 9/4/2025 to remind.|| || ||GC|| || | |||
|(1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS | |(1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS | ||
|(1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital | |(1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital | ||
| Line 1,867: | Line 2,137: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Intravascular large B-cell lymphoma|Intravascular large B-cell lymphoma]]||Disease|| | |[[HAEM5:Intravascular large B-cell lymphoma|Intravascular large B-cell lymphoma]]||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland | ||
| | | |5/6/2025 | ||
|8/6/2025 Emailed 9/4/2025 to remind | |||
| || ||GC|| || | |||
|Intravascular Large B-cell Lymphoma | |Intravascular Large B-cell Lymphoma | ||
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy | |Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy | ||
| Line 1,889: | Line 2,161: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:High-grade B-cell lymphoma, NOS|High-grade B-cell lymphoma, NOS]]||Disease|| | |[[HAEM5:High-grade B-cell lymphoma, NOS|High-grade B-cell lymphoma, NOS]]||Disease|| | ||
| || || || ||GC|| || | | || || || ||GC|| || | ||
|High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS) | |High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS) | ||
|Aiko Otsubo, PhD, Indiana University, Holli Drendel | |Aiko Otsubo, PhD, Indiana University, Holli Drendel | ||
|Complete | |Complete | ||
|16/11/2021 | |16/11/2021 Emailed 5/6/2025, no reply | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Burkitt lymphoma|Burkitt lymphoma]]||Disease|| | |[[HAEM5:Burkitt lymphoma|Burkitt lymphoma]]||Disease|| | ||
| || || || ||GC|| || | | || || || ||GC|| || | ||
|Burkitt Lymphoma | |Burkitt Lymphoma | ||
|Becky Leung, MBBS (Hons), BSc, Pathology Queensland | |Becky Leung, MBBS (Hons), BSc, Pathology Queensland | ||
|Complete | |Complete | ||
|28/06/2021 | |28/06/2021 Emailed 5/6/2025, no reply | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Primary effusion lymphoma|Primary effusion lymphoma]]||Disease|| || || || || ||GC|| || | !Disease (5th Edition) | ||
|NEW (No Prior) | !Page Type | ||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
|[[HAEM5:Primary effusion lymphoma|Primary effusion lymphoma]]||Disease|| || || || || ||GC|| || | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 1,963: | Line 2,251: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Classic Hodgkin lymphoma|Classic Hodgkin lymphoma]]||Disease|| | |[[HAEM5:Classic Hodgkin lymphoma|Classic Hodgkin lymphoma]]||Disease||Xiaolin Hu | ||
| | | |5/7/2025 | ||
|8/7/2025 Reminder email sent 9/4/2025|| || | |||
|GC|| ||Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma | |GC|| ||Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma | ||
|(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma | |(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma | ||
| Line 1,972: | Line 2,261: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Nodular lymphocyte predominant Hodgkin lymphoma|Nodular lymphocyte predominant Hodgkin lymphoma]]||Disease|| || || | |[[HAEM5:Nodular lymphocyte predominant Hodgkin lymphoma|Nodular lymphocyte predominant Hodgkin lymphoma]]||Disease||Muhammad Zulfiqar, MD | ||
|7/4/2025 | |||
|10/4/2025 Reminder email sent 9/4/2025||Pending|| ||GC|| || | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 1,978: | Line 2,269: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:Cold agglutinin disease|Cold agglutinin disease]] | |[[HAEM5:Cold agglutinin disease|Cold agglutinin disease]] | ||
| Line 2,017: | Line 2,324: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Immunoglobulin-related (AL) amyloidosis|Immunoglobulin-related (AL) amyloidosis]]||Disease|| | |[[HAEM5:Immunoglobulin-related (AL) amyloidosis|Immunoglobulin-related (AL) amyloidosis]]||Disease|| | ||
| || || || ||SG | | || || || ||SG | ||
| || | | || | ||
| Line 2,026: | Line 2,333: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Monoclonal immunoglobulin deposition disease|Monoclonal immunoglobulin deposition disease]]||Disease|| | |[[HAEM5:Monoclonal immunoglobulin deposition disease|Monoclonal immunoglobulin deposition disease]]||Disease|| | ||
| || || || ||SG | | || || || ||SG | ||
| || | | || | ||
| Line 2,043: | Line 2,350: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Gamma heavy chain disease|Gamma heavy chain disease]]||Disease|| | |[[HAEM5:Gamma heavy chain disease|Gamma heavy chain disease]]||Disease|| | ||
| || || || ||SG | | || || || ||SG | ||
| || | | || | ||
| Line 2,060: | Line 2,367: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Plasmacytoma|Plasmacytoma]]||Disease|| | |[[HAEM5:Plasmacytoma|Plasmacytoma]]||Disease|| | ||
| || || || | | || || || | ||
|SG | |SG | ||
| Line 2,070: | Line 2,377: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease|| | |[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease||Huan Mo; | ||
| || | | Zhenya Tang | ||
|4/14/25||7/14/25 | |||
9/4/2025 Sent E-mail reminder to Dr. Tang | |||
|Pending|| ||SG | |||
| ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page | | ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page | ||
|(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants | |(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants | ||
| Line 2,080: | Line 2,390: | ||
|- | |- | ||
|[[HAEM5:Plasma cell neoplasms with associated paraneoplastic syndrome|Plasma cell neoplasms with associated paraneoplastic syndrome]]||Disease||PENDING | |[[HAEM5:Plasma cell neoplasms with associated paraneoplastic syndrome|Plasma cell neoplasms with associated paraneoplastic syndrome]]||Disease||PENDING | ||
| || | | ||9/4/2025 E-mail sent to Dr. Senaratne | ||
| || | |||
|SG | |SG | ||
| ||Note: author needs to include POEMS, TEMPI, and look for AESOP content | | ||Note: author needs to include POEMS, TEMPI, and look for AESOP content | ||
| Line 2,105: | Line 2,416: | ||
|Prior Notes (4th Edition) | |Prior Notes (4th Edition) | ||
|- | |- | ||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
| | |- | ||
| colspan="15" | | |||
| | ====CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)==== | ||
|- | |||
| | |[[HAEM5:Kikuchi-Fujimoto disease|Kikuchi-Fujimoto disease]]||Disease|| Sumire Kitahara, MD|| || || '''Complete'''|| 11/6/2025||Sumi Kitahara (SK) | ||
-- | | || | ||
|NEW (No Prior) | |||
|- | |||
|[[HAEM5:Kikuchi-Fujimoto disease|Kikuchi-Fujimoto disease]]||Disease|| || || || || ||Sumi Kitahara (SK) | |||
| || | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,143: | Line 2,443: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Autoimmune lymphoproliferative syndrome|Autoimmune lymphoproliferative syndrome]]||Disease||Aviv Oren, MD (trainee) | |[[HAEM5:Autoimmune lymphoproliferative syndrome|Autoimmune lymphoproliferative syndrome]]||Disease||Aviv Oren, MD (trainee); | ||
Karin Miller, MD | |||
|3/25/2024 | |3/25/2024 | ||
| || | | ||Pending | ||
| ||SK|| || | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,171: | Line 2,473: | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|SK | |SK | ||
| Line 2,184: | Line 2,486: | ||
|[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]] | |[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]] | ||
|Disease | |Disease | ||
|Parastou Tizro, MD | |Parastou Tizro, MD; | ||
| | Celeste Eno, PhD; Sumire Kitahara, MD | ||
| | |9/23/2025 | ||
| | |11/4/2025 | ||
| | |'''Complete''' | ||
|11/4/2025 | |||
|SK | |SK | ||
| | |11/6/2025 | ||
| | | | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,198: | Line 2,501: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:T-large granular lymphocytic leukaemia|T-large granular lymphocytic leukaemia]]||Disease||Michelle Don, MD, MS | |[[HAEM5:T-large granular lymphocytic leukaemia|T-large granular lymphocytic leukaemia]]||Disease||Nicolas LaScala (trainee); | ||
| | Michelle Don, MD, MS | ||
| | |9/24/2025 | ||
|12/9/2025 | |||
|Pending | |Pending | ||
| ||SK|| || | | ||SK|| || | ||
| Line 2,211: | Line 2,515: | ||
|[[HAEM5:NK-large granular lymphocytic leukaemia|NK-large granular lymphocytic leukaemia]]||Disease||Hailee St. Louis (trainee); | |[[HAEM5:NK-large granular lymphocytic leukaemia|NK-large granular lymphocytic leukaemia]]||Disease||Hailee St. Louis (trainee); | ||
Michelle Don, MD, MS | Michelle Don, MD, MS | ||
| | |9/24/2025 | ||
| | |12/9/2025 | ||
| | |'''Complete''' | ||
| ||SK|| || | | 12/17/2025||SK|| 1/6/2026|| | ||
|Chronic Lymphoproliferative Disorder of NK Cells | |Chronic Lymphoproliferative Disorder of NK Cells | ||
|Michelle Don, MD | |Michelle Don, MD | ||
| Line 2,221: | Line 2,525: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Adult T-cell leukaemia/lymphoma|Adult T-cell leukaemia/lymphoma]]||Disease|| | |[[HAEM5:Adult T-cell leukaemia/lymphoma|Adult T-cell leukaemia/lymphoma]]||Disease||Sumire Kitahara, MD | ||
| || | |9/23/2025 | ||
|11/30/2025 | |||
|Pending | |||
| ||SK|| || | |||
|Adult T-cell Leukemia/Lymphoma | |Adult T-cell Leukemia/Lymphoma | ||
|Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG Vanderbilt University Medical Center | |Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG Vanderbilt University Medical Center | ||
| Line 2,231: | Line 2,538: | ||
|[[HAEM5:Sezary syndrome|Sezary syndrome]]||Disease||Daynna J. Wolff, PhD | |[[HAEM5:Sezary syndrome|Sezary syndrome]]||Disease||Daynna J. Wolff, PhD | ||
|3/22/2024 | |3/22/2024 | ||
| | |follow-up needed | ||
| || ||SK|| || | |||
|Sézary Syndrome | |Sézary Syndrome | ||
|Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina | |Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina | ||
| Line 2,238: | Line 2,546: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Aggressive NK-cell leukaemia|Aggressive NK-cell leukaemia]]||Disease|| | |[[HAEM5:Aggressive NK-cell leukaemia|Aggressive NK-cell leukaemia]]||Disease||Shashirekha Shetty, PhD | ||
| | |10/15/2025||1/19/2026 | ||
|Pending | |||
| ||SK|| || | | ||SK|| || | ||
|Aggressive NK-cell Leukemia | |Aggressive NK-cell Leukemia | ||
| Line 2,247: | Line 2,556: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease|| | !Disease (5th Edition) | ||
| | !Page Type | ||
| || | !<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | ||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Ian King, PhD | |||
|1/6/2026 | |||
| 2/3/2026|| | |||
| ||SK|| || | | ||SK|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,257: | Line 2,582: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder]]||Disease||Ahmed Eladely (trainee) | |[[HAEM5:Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder]]||Disease||Ahmed Eladely (trainee); | ||
Andrew Siref, MD | Andrew Siref, MD | ||
| | |10/14/2025 | ||
| | | |11/24/2025 | ||
| ||SK|| || | |'''Complete''' | ||
| 12/29/2025||SK|| 1/6/2026|| | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,271: | Line 2,597: | ||
|[[HAEM5:Mycosis fungoides|Mycosis fungoides]]||Disease||Daynna J. Wolff, PhD | |[[HAEM5:Mycosis fungoides|Mycosis fungoides]]||Disease||Daynna J. Wolff, PhD | ||
|3/22/2024 | |3/22/2024 | ||
| || || ||SK|| || | |follow-up needed|| || ||SK|| || | ||
|Mycosis Fungoides | |Mycosis Fungoides | ||
|Jane Scribner, MD and Daynna J. Wolff, PhD | |Jane Scribner, MD and Daynna J. Wolff, PhD | ||
| Line 2,278: | Line 2,604: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis]]||Disease||Rabail Aslam, MD (fellow); Shashirekha Shetty, PhD | |[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis]]||Disease||Rabail Aslam, MD (fellow); | ||
| || | Shashirekha Shetty, PhD | ||
|7/1/2024 | |||
|follow-up needed | |||
| | |||
| ||SK|| || | | ||SK|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,287: | Line 2,616: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma]]||Disease||Rabail Aslam, MD (fellow); Shashirekha Shetty, PhD | |[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma]]||Disease||Rabail Aslam, MD (fellow); | ||
| || | | Shashirekha Shetty, PhD | ||
|7/1/2024||follow-up needed | |||
| | |||
| ||SK|| || | | ||SK|| || | ||
|Primary Cutaneous Anaplastic Large Cell Lymphoma | |Primary Cutaneous Anaplastic Large Cell Lymphoma | ||
| Line 2,296: | Line 2,627: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease|| | |[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Ian King, PhD | ||
| | Katelyn Swanson, DO (trainee) | ||
| | | |11/19/2025 | ||
| ||SK|| || | |12/19/2025 | ||
|'''Complete''' | |||
| 1/6/2026||SK|| 1/6/2026|| | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,306: | Line 2,639: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Primary cutaneous gamma/delta T-cell lymphoma|Primary cutaneous gamma/delta T-cell lymphoma]]||Disease||Mahzad Azimpouran (trainee); Sumire Kitahara, MD | |[[HAEM5:Primary cutaneous gamma/delta T-cell lymphoma|Primary cutaneous gamma/delta T-cell lymphoma]]||Disease||Mahzad Azimpouran (trainee); | ||
| || | Sumire Kitahara, MD | ||
|6/30/2024 | |||
|11/9/2025 | |||
|Pending | |||
| ||SK|| || | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,314: | Line 2,651: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma]]||Disease||Ahmed Eladely (trainee) | |[[HAEM5:Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma]]||Disease||Ahmed Eladely (trainee); | ||
Andrew Siref, MD | Andrew Siref, MD | ||
| | |10/14/2025||11/24/2025 | ||
| ||SK|| || | |'''Complete''' | ||
| 12/29/2025||SK|| 1/6/2026|| | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,331: | Line 2,669: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract|Indolent T-cell lymphoma of the gastrointestinal tract]]||Disease|| | |[[HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract|Indolent T-cell lymphoma of the gastrointestinal tract]]||Disease|| | ||
| Line 2,347: | Line 2,701: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Enteropathy-associated T-cell lymphoma|Enteropathy-associated T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee) | |[[HAEM5:Enteropathy-associated T-cell lymphoma|Enteropathy-associated T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee); | ||
Andrew Siref, MD | Andrew Siref, MD | ||
| | |10/14/2025 | ||
| ||Pending|| ||SK|| || | | ||Pending|| ||SK|| || | ||
|Enteropathy-Associated T-cell Lymphoma | |Enteropathy-Associated T-cell Lymphoma | ||
| Line 2,357: | Line 2,711: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Monomorphic epitheliotropic intestinal T-cell lymphoma|Monomorphic epitheliotropic intestinal T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee) | |[[HAEM5:Monomorphic epitheliotropic intestinal T-cell lymphoma|Monomorphic epitheliotropic intestinal T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee); | ||
Andrew Siref, MD | Andrew Siref, MD | ||
| | |10/14/2025 | ||
| ||Pending|| ||SK|| || | | ||Pending|| ||SK|| || | ||
|Monomorphic Epitheliotropic Intestinal T-cell Lymphoma | |Monomorphic Epitheliotropic Intestinal T-cell Lymphoma | ||
| Line 2,370: | Line 2,724: | ||
| || || || ||SK|| || | | || || || ||SK|| || | ||
|Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS) | |Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS) | ||
|Derick Okwan MD, PhD (Stanford | |Derick Okwan MD, PhD (Stanford) Sumire Kitahara MD (Cedars-Sinai) | ||
|Complete | |Complete | ||
|9/26/2022 | |9/26/2022 | ||
| Line 2,377: | Line 2,731: | ||
|[[HAEM5:Hepatosplenic T-cell lymphoma|Hepatosplenic T-cell lymphoma]]||Disease||Forough Sargolzaeiaval (trainee); | |[[HAEM5:Hepatosplenic T-cell lymphoma|Hepatosplenic T-cell lymphoma]]||Disease||Forough Sargolzaeiaval (trainee); | ||
Michelle Don, MD, MS | Michelle Don, MD, MS | ||
| | |9/24/2025 | ||
| | |11/9/2025 | ||
| | |'''Complete''' | ||
| | |12/17/2025 | ||
|SK||1/6/2026|| | |||
|Hepatosplenic T-cell Lymphoma | |Hepatosplenic T-cell Lymphoma | ||
|Michelle Don, MD, MS | |Michelle Don, MD, MS | ||
| Line 2,387: | Line 2,742: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee) | |[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee); | ||
Sumire Kitahara, MD | Sumire Kitahara, MD | ||
|6/6/24|| || | |6/6/24|| || | ||
| ||SK|| || | | ||SK|| || | ||
|Anaplastic Large Cell Lymphoma, ALK-Positive | |Anaplastic Large Cell Lymphoma, ALK-Positive | ||
| Line 2,402: | Line 2,757: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee) | |[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee); | ||
Sumire Kitahara, MD | Sumire Kitahara, MD | ||
|6/6/24|| || | |6/6/24|| || | ||
| ||SK|| || | | ||SK|| || | ||
|Anaplastic Large Cell Lymphoma, ALK-Negative | |Anaplastic Large Cell Lymphoma, ALK-Negative | ||
| Line 2,413: | Line 2,768: | ||
|- | |- | ||
|[[HAEM5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||Lynne Abruzzo, MD, PhD | |[[HAEM5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||Lynne Abruzzo, MD, PhD | ||
| | |9/22/2025 | ||
|1/1/2026 | |||
|Pending|| ||SK|| || | |||
|Breast Implant-Associated Anaplastic Large Cell Lymphoma | |Breast Implant-Associated Anaplastic Large Cell Lymphoma | ||
|Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center | |Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center | ||
| Line 2,420: | Line 2,776: | ||
| | | | ||
| | | | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023 | |[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023 | ||
| | | |follow-up needed | ||
| || ||SK|| ||prior authors not available | |||
|Angioimmunoblastic T-cell Lymphoma | |Angioimmunoblastic T-cell Lymphoma | ||
|Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG | |Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG | ||
| Line 2,430: | Line 2,803: | ||
|- | |- | ||
|[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease||Rachel Burnside, PhD||7/28/2023 | |[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease||Rachel Burnside, PhD||7/28/2023 | ||
| | | |follow-up needed | ||
| || ||SK|| || | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,446: | Line 2,820: | ||
|- | |- | ||
|[[HAEM5:Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, NOS]]||Disease||Bo Hong, MD | |[[HAEM5:Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, NOS]]||Disease||Bo Hong, MD | ||
| | |10/14/2025 | ||
| | | |12/3/2025 | ||
|Pending | |||
| ||SK|| || | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,454: | Line 2,830: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:EBV-positive nodal T- and NK-cell lymphoma|EBV-positive nodal T- and NK-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee) | |[[HAEM5:EBV-positive nodal T- and NK-cell lymphoma|EBV-positive nodal T- and NK-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee); | ||
Andrew Siref, MD | |||
|10/14/2025|| ||Pending|| ||SK|| || | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,461: | Line 2,839: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease|| | |[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease||Maryam Mehdiopour Dalivand (trainee); Ian King, PhD | ||
| | |1/6/2026 | ||
| ||Pending | | 2/3/2026||Pending | ||
| ||SK|| || | | ||SK|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,487: | Line 2,865: | ||
|[[HAEM5:Systemic chronic active EBV disease|Systemic chronic active EBV disease]]||Disease||Karin Miller, MD | |[[HAEM5:Systemic chronic active EBV disease|Systemic chronic active EBV disease]]||Disease||Karin Miller, MD | ||
|3/25/2024 | |3/25/2024 | ||
| || | | 11/17/2025||Pending | ||
| ||SK|| || | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,496: | Line 2,875: | ||
|[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||Karin Miller, MD | |[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||Karin Miller, MD | ||
|3/25/2024 | |3/25/2024 | ||
| || | | 11/17/2025||Pending | ||
| ||SK|| ||prior authors not available | |||
|Systemic EBV-Positive T-cell Lymphoma of Childhood | |Systemic EBV-Positive T-cell Lymphoma of Childhood | ||
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA | |Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA | ||
| Line 2,503: | Line 2,883: | ||
| | | | ||
|- | |- | ||
|CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES) | !Disease (5th Edition) | ||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
| | |||
====CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES)==== | |||
| | | | ||
----<br /> | ----<br /> | ||
| Line 2,535: | Line 2,932: | ||
|[[HAEM5:Follicular dendritic cell sarcoma|Follicular dendritic cell sarcoma]] | |[[HAEM5:Follicular dendritic cell sarcoma|Follicular dendritic cell sarcoma]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 2,645: | Line 3,042: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|CHAPTER 7 (GENETIC TUMOUR SYNDROMES) | !Disease (5th Edition) | ||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
| | |||
====CHAPTER 7 (GENETIC TUMOUR SYNDROMES)==== | |||
| | | | ||
----<br /> | ----<br /> | ||
| Line 2,675: | Line 3,089: | ||
----<br /> | ----<br /> | ||
|- | |- | ||
|[[HAEM5:Fanconi anaemia|Fanconi anaemia]]||Disease|| | |[[HAEM5:Fanconi anaemia|Fanconi anaemia]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
| | |N/A||N/A | ||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,683: | Line 3,102: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Bloom syndrome|Bloom syndrome]]||Disease|| | |[[HAEM5:Bloom syndrome|Bloom syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
| | |N/A | ||
| || || | |N/A | ||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,692: | Line 3,116: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Ataxia-telangiectasia syndrome|Ataxia-telangiectasia syndrome]]||Disease|| || || || || || | |[[HAEM5:Ataxia-telangiectasia syndrome|Ataxia-telangiectasia syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]]||N/A||N/A||N/A||N/A||N/A||N/A||N/A | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||